RU2019100079A - Способ получения днк-вакцины для иммунотерапии рака - Google Patents
Способ получения днк-вакцины для иммунотерапии рака Download PDFInfo
- Publication number
- RU2019100079A RU2019100079A RU2019100079A RU2019100079A RU2019100079A RU 2019100079 A RU2019100079 A RU 2019100079A RU 2019100079 A RU2019100079 A RU 2019100079A RU 2019100079 A RU2019100079 A RU 2019100079A RU 2019100079 A RU2019100079 A RU 2019100079A
- Authority
- RU
- Russia
- Prior art keywords
- antigen
- clone
- dna molecule
- transformed cell
- expression cassette
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 14
- 238000002619 cancer immunotherapy Methods 0.000 title claims 5
- 229960005486 vaccine Drugs 0.000 title 1
- 239000000427 antigen Substances 0.000 claims 31
- 102000036639 antigens Human genes 0.000 claims 31
- 108091007433 antigens Proteins 0.000 claims 31
- 108020004414 DNA Proteins 0.000 claims 16
- 210000004027 cell Anatomy 0.000 claims 16
- 102000053602 DNA Human genes 0.000 claims 14
- 239000012634 fragment Substances 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 241000607142 Salmonella Species 0.000 claims 4
- 230000001580 bacterial effect Effects 0.000 claims 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims 4
- 108010041986 DNA Vaccines Proteins 0.000 claims 3
- 229940021995 DNA vaccine Drugs 0.000 claims 3
- 230000002238 attenuated effect Effects 0.000 claims 3
- 229920001817 Agar Polymers 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims 2
- 239000008272 agar Substances 0.000 claims 2
- 238000011109 contamination Methods 0.000 claims 2
- 230000002538 fungal effect Effects 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 239000006152 selective media Substances 0.000 claims 2
- 238000012163 sequencing technique Methods 0.000 claims 2
- 238000001890 transfection Methods 0.000 claims 2
- ZPLCXHWYPWVJDL-UHFFFAOYSA-N 4-[(4-hydroxyphenyl)methyl]-1,3-oxazolidin-2-one Chemical compound C1=CC(O)=CC=C1CC1NC(=O)OC1 ZPLCXHWYPWVJDL-UHFFFAOYSA-N 0.000 claims 1
- 102000003839 Human Proteins Human genes 0.000 claims 1
- 108090000144 Human Proteins Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 241001138501 Salmonella enterica Species 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 239000006285 cell suspension Substances 0.000 claims 1
- 238000004520 electroporation Methods 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 229930027917 kanamycin Natural products 0.000 claims 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims 1
- 229960000318 kanamycin Drugs 0.000 claims 1
- 229930182823 kanamycin A Natural products 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Pregnancy & Childbirth (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16001550.9 | 2016-07-13 | ||
| EP16001550 | 2016-07-13 | ||
| PCT/EP2017/067590 WO2018011289A1 (en) | 2016-07-13 | 2017-07-12 | Process for the production of a dna vaccine for cancer immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2019100079A true RU2019100079A (ru) | 2020-08-13 |
Family
ID=56418345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019100079A RU2019100079A (ru) | 2016-07-13 | 2017-07-12 | Способ получения днк-вакцины для иммунотерапии рака |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10821163B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3484503A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7098599B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20190027834A (cg-RX-API-DMAC7.html) |
| CN (1) | CN109475614A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017295004B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019000657A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3028549A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL263568A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019000415A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2019100079A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201811258UA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018011289A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3050833A1 (en) | 2017-02-17 | 2018-08-23 | Vaximm Ag | Novel vegfr-2 targeting immunotherapy approach |
| WO2019014398A1 (en) | 2017-07-11 | 2019-01-17 | Actym Therapeutics, Inc. | MODIFIED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF |
| AU2019301699C1 (en) | 2018-07-11 | 2024-10-10 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| AU2019334131B2 (en) | 2018-09-05 | 2025-12-18 | NEC Oncolmmunity AS | Neoantigen targeting DNA vaccine for combination therapy |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| WO2021144254A1 (en) | 2020-01-13 | 2021-07-22 | Vaximm Ag | Salmonella-based dna vaccines in combination with an antibiotic |
| JPWO2024005122A1 (cg-RX-API-DMAC7.html) * | 2022-06-30 | 2024-01-04 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT4223311T (pt) * | 2011-05-24 | 2025-08-21 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh | Vacinas individualizadas para o cancro |
| MX355134B (es) * | 2011-12-22 | 2018-04-06 | Vaximm Ag | Metodo para producir cepas atenuadas de salmonella con alto rendimiento. |
| US9415098B2 (en) * | 2012-07-05 | 2016-08-16 | Vaximm Ag | DNA vaccine for use in pancreatic cancer patients |
| JP6416877B2 (ja) * | 2013-04-25 | 2018-10-31 | バクシム アクチェンゲゼルシャフト | ウィルムス腫瘍遺伝子ｗｔ１を標的とする癌免疫療法用のサルモネラベースのベクター |
| JP6662787B2 (ja) * | 2013-12-18 | 2020-03-11 | バキシム ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌免疫療法のための新規ｍｓｌｎ標的化ｄｎａワクチン |
| NZ721908A (en) * | 2013-12-20 | 2022-12-23 | Massachusetts Gen Hospital | Combination therapy with neoantigen vaccine |
-
2017
- 2017-07-12 KR KR1020197002050A patent/KR20190027834A/ko not_active Ceased
- 2017-07-12 CN CN201780043297.1A patent/CN109475614A/zh active Pending
- 2017-07-12 CA CA3028549A patent/CA3028549A1/en active Pending
- 2017-07-12 BR BR112019000657-5A patent/BR112019000657A2/pt not_active Application Discontinuation
- 2017-07-12 JP JP2019501917A patent/JP7098599B2/ja active Active
- 2017-07-12 EP EP17743277.0A patent/EP3484503A1/en active Pending
- 2017-07-12 US US16/315,606 patent/US10821163B2/en active Active
- 2017-07-12 WO PCT/EP2017/067590 patent/WO2018011289A1/en not_active Ceased
- 2017-07-12 MX MX2019000415A patent/MX2019000415A/es unknown
- 2017-07-12 RU RU2019100079A patent/RU2019100079A/ru not_active Application Discontinuation
- 2017-07-12 KR KR1020237018125A patent/KR20230079514A/ko not_active Ceased
- 2017-07-12 SG SG11201811258UA patent/SG11201811258UA/en unknown
- 2017-07-12 AU AU2017295004A patent/AU2017295004B2/en active Active
-
2018
- 2018-12-06 IL IL263568A patent/IL263568A/en unknown
-
2020
- 2020-09-29 US US17/037,627 patent/US11590215B2/en active Active
-
2022
- 2022-04-28 JP JP2022074854A patent/JP2022097591A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019521154A (ja) | 2019-07-25 |
| JP2022097591A (ja) | 2022-06-30 |
| MX2019000415A (es) | 2019-03-28 |
| EP3484503A1 (en) | 2019-05-22 |
| US11590215B2 (en) | 2023-02-28 |
| JP7098599B2 (ja) | 2022-07-11 |
| CN109475614A (zh) | 2019-03-15 |
| WO2018011289A1 (en) | 2018-01-18 |
| SG11201811258UA (en) | 2019-01-30 |
| IL263568A (en) | 2019-01-31 |
| US20220072112A1 (en) | 2022-03-10 |
| CA3028549A1 (en) | 2018-01-18 |
| AU2017295004A1 (en) | 2019-01-03 |
| KR20230079514A (ko) | 2023-06-07 |
| US10821163B2 (en) | 2020-11-03 |
| US20190183996A1 (en) | 2019-06-20 |
| AU2017295004B2 (en) | 2020-08-13 |
| KR20190027834A (ko) | 2019-03-15 |
| BR112019000657A2 (pt) | 2019-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019100079A (ru) | Способ получения днк-вакцины для иммунотерапии рака | |
| JP2019521154A5 (cg-RX-API-DMAC7.html) | ||
| ES2654664T3 (es) | Cepas de Pichia pastoris para la producción de una estructura de glicano predominantemente homogénea | |
| US20200263162A1 (en) | Method for preparing electrocompetent yeast cells, and method for using said cells | |
| CN103757053B (zh) | 一种特异性的dna病毒基因组定点改造及筛选方法 | |
| CN109536463A (zh) | 鸭瘟病毒gE和gI双基因无痕缺失株DPV CHv-ΔgE+ΔgI及其构建方法 | |
| CN114164184B (zh) | 一种新城疫病毒基因ⅵ型疫苗株及其应用 | |
| CN108165551B (zh) | 一种改进的启动子及其组成的t载体和应用 | |
| CN108728477B (zh) | 一种高效的转座突变系统及构建方法 | |
| CN103352050B (zh) | 利用细菌人工染色体同源重组提高细胞转染效率的方法 | |
| CN114164182B (zh) | 一种基因vii型遗传拯救的新城疫病毒疫苗株 | |
| CN117586920B (zh) | 抗噬菌体群体侵染菌株、抗噬菌体元件及其应用 | |
| FR2604183A1 (fr) | Sequence d'adn, vecteurs, virus recombinants et procede mettant en oeuvre des virus de la vaccine recombinants capables de se multiplier dans les cellules cho | |
| CN109735477B (zh) | 单核细胞增生李斯特菌三基因缺失减毒突变株制备及其应用 | |
| EP2460878A1 (en) | Orf7 deficient varicella virus, vaccine comprising the virus and use thereof | |
| CN119082073A (zh) | 一种耐高温mmlv逆转录酶突变体及其应用 | |
| CN109593730A (zh) | 鸭瘟病毒Lorf5基因无痕缺失株DPV CHv-ΔLorf5及其构建方法 | |
| CN117683813A (zh) | Df-1细胞中ee0.6位点敲除载体和nc_006127.4位点敲除载体 | |
| CN109182153A (zh) | 一种高毒力蝗绿僵菌工程菌株及其构建方法 | |
| CN114163506A (zh) | 施氏假单胞杆菌来源的PsPIWI-RE蛋白在介导同源重组上的应用 | |
| CN110579608B (zh) | 一种筛选高表达外源蛋白的非整合减毒李斯特菌菌株的方法 | |
| CN104388459B (zh) | 使细菌自主产微细胞的方法及一株自产微细胞细菌突变株 | |
| CN109609547A (zh) | 鸭瘟病毒Lorf5基因无痕缺失株CHv-BAC-G-ΔLorf5及其构建方法 | |
| CN116064898B (zh) | 一种检测大豆表皮毛形态的分子标记及其应用 | |
| CN109628417A (zh) | 鸭瘟病毒gE和gI双基因无痕缺失株CHv-BAC-G-ΔgE+ΔgI及其构建方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20200713 |